The Potential Cardioprotective Effect of Addition of Atorvastatin in Breast Cancer Patients Treated With Doxorubicin-based Chemotherapy

female patients with newly diagnosed breast cancer, who are candidates for AC protocol will be recruited from Damanhour oncology center.

All enrolled patients will be randomly assigned into 2 arms:

• Control arm : will receive AC regimen only (doxorubicin 60 mg/m² IV + cyclophosphamide 600 mg/m² IV) for 4 cycles every 21 days.
• Atorvastatin arm : will receive AC regimen mentioned above + atorvastatin 40 mg orally once daily for 3 months.

All patients will be submitted to:

• Full patient history and clinical examination.
• Routine follow up before and after each chemotherapy cycle (complete blood picture, liver function tests, renal function tests).
• Echocardiography also will be obtained at the time of admission.
• Serum samples will be collected from patients at the time of admission for measuring the cardiac biomarkers in addition to serum cholesterol level.